JBC: A molecular dance of phospholipid synthesis
The most abundant molecule in cell membranes is the lipid phosphatidylcholine, or PC, commonly known as lecithin; accordingly, the enzymes responsible for synthesizing it are essential. Research published in the Journal of Biological Chemistry used computer simulations to gain insights into how one of these enzymes activates and shuts off PC production. The results could help researchers understand why small changes in this enzyme can lead to conditions like blindness and dwarfism.
Rosemary Cornell, a professor of molecular biology and biochemistry at Simon Fraser University in Canada, studies the enzyme CTP:phosphocholine cytidylyltransferase, or CCT. CCT sets the rate of PC production in cells by binding to cell membranes with low PC content. When bound to membranes, the CCT enzyme changes shape in a way that allows it to carry out the key rate-limiting step in PC synthesis. When the amount of PC making up the membrane increases, the CCT falls off the membrane, and PC production ceases.
“The membrane is this big macromolecular array with lots of different molecules in it,” Cornell said. “How does this enzyme recognize that ‘Oh, I should slow down because the PC content of the membrane is getting too high?’”
Cornell and her project team — a collaboration with Peter Tieleman and graduate student Mohsen Ramezanpour at the University of Calgary and Jaeyong Lee and Svetla Taneva, research associates at SFU — thought the answer must have to do with the enzyme’s dynamic changes in shape when it binds to a membrane. But these changes are difficult to capture with traditional structural biology methods such as X-ray crystallography, which take a static snapshot of molecules. Instead, the team used computational simulations of molecular dynamics, which use information about the forces between every individual atom in a molecule to calculate the trajectories of the enzyme’s moving parts.
“What it looks like (when you visualize the output) is your big molecule dancing in front of your eyes,” Cornell said. “We set up the molecular dynamics simulation not once, not twice, but 40 different (times). It took months and months just to do the computational parts and even more months trying to analyze the data afterward. We actually spent a lot of time once we got the data just looking on the screen at these dancing molecules.”
The simulated dance of the CCT molecule showed that when the M-domain, the section of the enzyme that typically binds to the membrane, detaches from a membrane, it snags the active site of the enzyme, preventing it from carrying out its reaction. When the snagging segment was removed from the simulation, the team saw a dramatic bending motion in the docking site for the snagging element and speculated that this bending would create a better enzyme active site for catalyzing the reaction when attached to a membrane. They confirmed these mechanisms with biochemical laboratory experiments.
Previous genetic studies had shown that mutations in the gene encoding CCT are responsible for rare conditions like spondylometaphyseal dysplasia with cone-rod dystrophy, which causes severe impairments in bone growth and vision, but it was not known how these changes in the enzyme could lead to such dramatic consequences. Cornell hopes that understanding how the enzyme works could help researchers find the causes of these conditions.
“If you have just one small change in CCT, then how is that going to make this whole process of synthesizing PC defective?” she asked. “That’s what we’re studying right now.”
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
As COVID-19 shuttered laboratories across the U.S., many researchers were forced to euthanize the animals they study. Lindsay Gray, a rodent surgeon in an animal research lab that faced this dilemma, argues here there is a safer, more effective way.
Early in adulthood, the brain regenerates lost myelin effectively, but remyelination falters with age. Researchers seek to understand why — and what the change may mean for people with multiple sclerosis.
Nearly 6 million Americans live with Alzheimer’s disease without solid treatment options.